Purification Platform Isolere Bio specializes in novel purification reagents (IsoTag) and ALPS technology for downstream bioprocessing bottlenecks, presenting an opportunity to expand filtration and separation capabilities for manufacturers producing viral vectors and mRNA.

Viral Vector Focus Active development and commercialization of IsoTag AAV reagents and lentiviral vector manufacturing solutions align with growing gene therapy pipelines, offering cross-sell potential to CDMO and biopharma clients pursuing AAV, LV, and AdV production improvements.

Acquisition Advantage As a Donaldson Life Sciences business since 2023, Isolere benefits from an established filtration ecosystem and distribution footprint, enabling joint go-to-market strategies, bundled filtration and purification solutions, and expanded customer reach.

Strategic Collaborations Past collaborations with Oxford Biomedica and participation in ASGCT events indicate readiness for co-development partnerships and tech validation within the gene therapy and vector manufacturing space.

Market Readiness Current revenue scale and recent leadership changes suggest an evolving go-to-market with emphasis on expanding customer base in biopharma and contract manufacturers, creating opportunities for pilots, trials, and early adopter programs around ALPS-based purification.